Cancer treatment statistics describe more than diagnoses and deaths. They also show how treatment is delivered, how outcomes differ by cancer type, and why patients and caregivers may face very different care journeys. The figures below distinguish recorded U.S. data, worldwide estimates, study findings, and 2026 projections.
Contents
- The overall cancer burden
- How cancer treatment is delivered
- Radiotherapy access and workforce needs
- Projected U.S. cases and deaths in 2026
- Survival statistics by cancer type
- What treatment patterns show
The overall cancer burden
The CDC Cancer Data and Statistics recorded 1,851,238 new cancer cases in the United States in 2022. In 2023, 613,349 people died of cancer in the United States. These are measured U.S. statistics for different years, so they should not be treated as a direct case-to-death ratio.
The CDC’s United States Cancer Statistics program covers more than 39 million new cancer cases and deaths. Its public use database includes cancer incidence and population data for all 50 states and the District of Columbia since 2001. That long time span helps researchers examine cancer patterns across places and years, while the individual statistics above remain tied to their stated measurement years.
The global picture is also substantial. The WHO Cancer fact sheet says cancer caused nearly 10 million deaths worldwide in 2020, accounting for nearly one in six deaths globally. WHO also reports that nearly a quarter of cancer deaths are due to tobacco use, alcohol consumption, high body mass index, low fruit and vegetable intake, and lack of physical activity. In low- and lower-middle-income countries, cancer-causing infections are responsible for approximately 30% of cancer cases.
These figures give caregivers important context: cancer is not one uniform condition. The likely treatment plan, duration of care, and support needs depend on the cancer type, stage, treatment response, and the health system providing care.
How cancer treatment is delivered
According to the WHO Cancer fact sheet, treatment usually includes surgery, radiotherapy, and/or systemic therapy. Systemic therapy includes chemotherapy, hormonal treatments, and targeted biological therapies. A patient may receive one approach or several, depending on the clinical situation.
WHO says many cancers can be cured if detected early and treated effectively. This statement does not provide one survival rate for every cancer; it describes the importance of early detection and effective treatment across cancer care. For families, it also helps explain why diagnosis, staging, treatment planning, follow-up, and symptom management are connected parts of the care experience.
The FORTY project provides one measured picture of treatment patterns among its patients. Overall cancer-specific 5-year survival was 52%. Surgery, alone or in combination, was the most common curative treatment, received by 80% of patients. Radiotherapy was received by 39%, and chemotherapy by 29%.
In the same project, 45% of patients received two treatment modalities and 13% received all three modalities. These percentages describe the FORTY project population, not every person with cancer. They nevertheless illustrate why caregiving can involve coordination among surgical teams, radiation services, medical oncology, rehabilitation, and home-based support.
Radiotherapy access and workforce needs
Radiotherapy is a major part of cancer treatment, but access varies by economic setting. The International Agency for Research on Cancer reports that radiotherapy is used in more than half of all cancer cases in high-income countries. Its estimates for scaling up radiotherapy in low- and middle-income countries cover 2015–2035.
| Income group | Estimated cost, 2015–2035 |
|---|---|
| Low-income countries | US$26.6 billion |
| Lower-middle-income countries | US$62.6 billion |
| Upper-middle-income countries | US$94.8 billion |
| All low- and middle-income countries | US$184.0 billion |
These are IARC estimates for investment over a defined period, not current annual spending and not a forecast of an individual patient’s treatment cost. The scale of the estimates reflects needs for equipment, facilities, staff, training, and service capacity.
The IAEA-led Lancet Oncology Commission reported that hypofractionation for prostate and breast cancer could provide radiotherapy for an additional 2.2 million patients. Hypofractionation refers to delivering treatment in fewer sessions; the statistic describes additional patient capacity associated with the commission’s analysis, not a guarantee that every patient can use that approach.
The commission also said the 2022 radiotherapy workforce would need to expand by more than 60% by 2050. Its projections include more than 84,000 radiation oncologists, 47,000 medical physicists, and 141,000 radiotherapy technologists by 2050. These are workforce projections, not counts of currently available clinicians.
For caregivers, access statistics can matter as much as treatment efficacy. A treatment plan may require repeated travel, appointment scheduling, transportation assistance, time away from work, or help managing side effects. Workforce and infrastructure constraints can shape how practical a recommended treatment is in a particular region.
Projected U.S. cases and deaths in 2026
The following figures are 2026 U.S. projections from SEER Cancer Stat Facts and the American Cancer Society estimate cited in the Common Cancer Sites material. They are projections, not completed counts. The American Cancer Society estimates 626,140 cancer deaths in the United States in 2026.
| Cancer type | Projected new cases | Projected deaths |
|---|---|---|
| Prostate | 333,830 | 36,320 |
| Female breast | 321,910 | 42,140 |
| Lung and bronchus | 229,410 | 124,990 |
| Colorectal | 158,850 | 55,230 |
| Melanoma of the skin | 112,000 | 8,510 |
| Pancreatic | 67,530 | 52,740 |
Prostate cancer is projected to be diagnosed 333,830 times and cause 36,320 deaths in 2026. SEER identifies it as the fifth leading cause of cancer death in the United States. Female breast cancer is projected to account for 321,910 new cases and 42,140 deaths. It represents 15.2% of all new U.S. cancer cases and 6.7% of all U.S. cancer deaths.
Lung and bronchus cancer is projected to have 229,410 new cases and 124,990 deaths. It represents 10.8% of all new U.S. cancer cases. Colorectal cancer is projected to have 158,850 new cases and 55,230 deaths, representing 7.6% of new cases and 8.8% of deaths. Melanoma of the skin is projected to have 112,000 new cases and 8,510 deaths, representing 5.3% of new cases.
Pancreatic cancer is projected to have 67,530 new cases and 52,740 deaths, representing 3.2% of all new U.S. cancer cases. The Common Cancer Sites and Pancreatic Cancer materials identify pancreatic cancer as the third deadliest cancer in the United States in the 2026 projection.
Other projected U.S. cancer deaths in 2026 include 23,910 from leukemia, 19,970 from non-Hodgkin lymphoma, 17,870 from bladder cancer, 15,160 from kidney and renal pelvis cancer, and 14,450 from uterine cancer. These figures help indicate the size of the populations for whom treatment and caregiving services may be needed, but they do not predict an individual outcome.
Survival statistics by cancer type
The American Cancer Society’s Cancer Statistics, 2026 reports that 5-year relative survival for all cancers combined increased from 49% in the mid-1970s to 70% during 2015–2021. “Relative survival” compares people with cancer with people in the general population; it is a population measure rather than a personal prognosis.
SEER reports a 5-year relative survival rate of 98% for prostate cancer. Female breast cancer has a 91.9% 5-year relative survival rate for 2016–2022. Melanoma of the skin has a 94.7% rate for 2016–2022. These measurement periods are explicit and should not be conflated with the 2026 case projections.
Pancreatic cancer has a 13.7% 5-year relative survival rate for 2016–2022 in SEER data. For localized pancreatic cancer, the 5-year relative survival rate is 43.6%. The difference shows why stage at diagnosis matters when interpreting cancer statistics.
The contemporary survival figures in Cancer Statistics, 2026 are 98% for thyroid cancer, 98% for prostate cancer, 95% for testis cancer, and 95% for melanoma. The corresponding figures are 28% for lung cancer, 22% for liver cancer, 22% for esophageal cancer, and 13% for pancreatic cancer.
These rates summarize groups over defined periods. They do not account for every difference in age, stage, treatment access, health status, or response to therapy. Caregivers can use them to understand broad patterns, but an oncology team is the appropriate source for an individual’s treatment outlook.
What treatment patterns show
Lung and bronchus cancer illustrates how demographic and timing details can sit behind a national total. SEER reports a new-case rate of 47.2 per 100,000 people per year based on 2019–2023 cases, and a death rate of 30.2 per 100,000 people per year based on 2020–2024 deaths. The median age at diagnosis is 71, while the median age at death is 73.
People aged 65–74 account for 36.4% of new lung and bronchus cancer cases, people aged 75–84 account for 28.4%, and people aged 55–64 account for 20.8%. The reported incidence rate is 63.7 per 100,000 among non-Hispanic Black men and 50.9 per 100,000 among non-Hispanic White women. These are subgroup statistics, and they should not be generalized to every patient.
The combined view is useful for caregiver support. U.S. cancer counts show the scale of care needs; survival statistics show that outcomes vary widely; treatment studies show that surgery, radiotherapy, chemotherapy, or combinations may be involved; and radiotherapy projections show that capacity and workforce remain important. Because the figures refer to different populations and periods, they are best used as context for questions about diagnosis, treatment options, expected appointments, side effects, transportation, and practical support.